Asciminib Elicits Safe and Durable Responses in Previously T

Treatment with asciminib elicited greater efficacy and had a more tolerable safety profile compared with bosutinib for patients chronic myeloid leukemia in chronic phase following treatment with 2 or more TKIs.

Related Keywords

, Michael Mauro , Memorial Sloan Kettering Cancer Center , Myeloproliferative Neoplasms Program , Ash Annual Meeting And Exposition , Conference , Oncology , News ,